{"id":70219,"date":"2026-04-13T15:30:43","date_gmt":"2026-04-13T10:00:43","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=70219"},"modified":"2026-04-13T15:30:45","modified_gmt":"2026-04-13T10:00:45","slug":"blogs-sun-pharma-target-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/","title":{"rendered":"Sun Pharma Share Price Target 2026: Analyst Consensus, Bull Case &amp; Bear Case"},"content":{"rendered":"<p>Sun Pharma (Pharmaceuticals \/ Specialty) is trading at Rs 1,580 as of April 2026, with a 52-week range from Rs 1,480 to Rs 2,000 and a 1-year return of -20%. The analyst consensus 12-month Sun Pharma share price target stands at Rs 1,900-2,100 \u2014 implying meaningful potential movement from current levels.<\/p><p>Whether you are a long-term holder reassessing your position or a new investor evaluating entry levels, understanding where analysts see Sun Pharma heading over the next 12-24 months requires looking beyond the CMP. This article covers the key catalysts and risks, technical levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term Sun Pharma share price targets.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2014 Get Free Investment Predictions on Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Sun_Pharma_Key_Data_%E2%80%94_CMP_Valuation_Fundamentals\" title=\"Sun Pharma Key Data \u2014 CMP, Valuation, Fundamentals\">Sun Pharma Key Data \u2014 CMP, Valuation, Fundamentals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Sun_Pharma_Share_Price_Targets_%E2%80%94_Short-Term_12-Month_Long-Term\" title=\"Sun Pharma Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term\">Sun Pharma Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Bull_Case_%E2%80%94_What_Has_to_Go_Right_for_Sun_Pharma\" title=\"Bull Case \u2014 What Has to Go Right for Sun Pharma\">Bull Case \u2014 What Has to Go Right for Sun Pharma<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#1_US_specialty_franchise_Ilumya_Cequa_Odomzo_generating_12_billion_and_growing_at_15_CC_annually\" title=\"1. US specialty franchise (Ilumya, Cequa, Odomzo) generating $1.2+ billion and growing at 15% CC annually\">1. US specialty franchise (Ilumya, Cequa, Odomzo) generating $1.2+ billion and growing at 15% CC annually<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#2_India_branded_generics_market_leadership_10_market_share_in_key_therapy_areas\" title=\"2. India branded generics market leadership (10%+ market share in key therapy areas)\">2. India branded generics market leadership (10%+ market share in key therapy areas)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#3_GLP-1_Semaglutide-class_obesity_drug_GL0034_in_Phase_2\" title=\"3. GLP-1 (Semaglutide-class) obesity drug GL0034 in Phase 2\">3. GLP-1 (Semaglutide-class) obesity drug GL0034 in Phase 2<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#4_Organon_acquisition_optionality\" title=\"4. Organon acquisition optionality\">4. Organon acquisition optionality<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#5_Emerging_market_specialty_expansion_in_dermatology_and_ophthalmology_across_45_countries\" title=\"5. Emerging market specialty expansion in dermatology and ophthalmology across 45+ countries\">5. Emerging market specialty expansion in dermatology and ophthalmology across 45+ countries<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Bear_Case_%E2%80%94_Key_Risks_to_the_Sun_Pharma_Share_Price_Target\" title=\"Bear Case \u2014 Key Risks to the Sun Pharma Share Price Target\">Bear Case \u2014 Key Risks to the Sun Pharma Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Risk_1_Ilumya_biosimilar_entry_in_FY27-28_materially_reducing_the_highest-margin_US_product_revenue\" title=\"Risk 1: Ilumya biosimilar entry in FY27-28 materially reducing the highest-margin US product revenue\">Risk 1: Ilumya biosimilar entry in FY27-28 materially reducing the highest-margin US product revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Risk_2_Organon_acquisition_completing_with_adverse_terms_creating_leveraged_balance_sheet_without_commensurate_earnings_accretion\" title=\"Risk 2: Organon acquisition completing with adverse terms, creating leveraged balance sheet without commensurate earnings accretion\">Risk 2: Organon acquisition completing with adverse terms, creating leveraged balance sheet without commensurate earnings accretion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Risk_3_US_26_pharma_tariff_expansion_beyond_APIs_to_finished_formulations\" title=\"Risk 3: US 26% pharma tariff expansion beyond APIs to finished formulations\">Risk 3: US 26% pharma tariff expansion beyond APIs to finished formulations<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Institutional_Sentiment_and_Technical_Analysis\" title=\"Institutional Sentiment and Technical Analysis\">Institutional Sentiment and Technical Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Conclusion_%E2%80%94_Our_View_on_name_Share_Price_Target\" title=\"Conclusion \u2014 Our View on ${name} Share Price Target\">Conclusion \u2014 Our View on ${name} Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Q1_What_is_Sun_Pharma_share_price_target_2026\" title=\"Q1. What is Sun Pharma share price target 2026?\">Q1. What is Sun Pharma share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Q2_Is_Sun_Pharma_a_good_buy_now\" title=\"Q2. Is Sun Pharma a good buy now?\">Q2. Is Sun Pharma a good buy now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Q3_What_is_Sun_Pharmas_current_valuation\" title=\"Q3. What is Sun Pharma&#8217;s current valuation?\">Q3. What is Sun Pharma&#8217;s current valuation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Q4_What_are_the_key_risks_for_Sun_Pharma\" title=\"Q4. What are the key risks for Sun Pharma?\">Q4. What are the key risks for Sun Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Q5_Where_can_I_track_Sun_Pharma_share_price_live\" title=\"Q5. Where can I track Sun Pharma share price live?\">Q5. Where can I track Sun Pharma share price live?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/blogs-sun-pharma-target-share-price-target-2026\/#Recent_Articles\" title=\"Recent Articles\">Recent Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sun_Pharma_Key_Data_%E2%80%94_CMP_Valuation_Fundamentals\"><\/span><strong>Sun Pharma Key Data \u2014 CMP, Valuation, Fundamentals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Parameter<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>CMP (April 2026)<\/td><td>Rs 1,580<\/td><\/tr><tr><td>52-Week High<\/td><td>Rs 2,000<\/td><\/tr><tr><td>52-Week Low<\/td><td>Rs 1,480<\/td><\/tr><tr><td>1-Year Return<\/td><td>-20%<\/td><\/tr><tr><td>Trailing P\/E<\/td><td>38x<\/td><\/tr><tr><td>Price-to-Book<\/td><td>6.8x<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 3.8L Cr<\/td><\/tr><tr><td>Sector<\/td><td>Pharmaceuticals \/ Specialty<\/td><\/tr><tr><td>Promoter Holding<\/td><td>54.5%<\/td><\/tr><tr><td>FII Holding<\/td><td>21.8%<\/td><\/tr><tr><td>DII Holding<\/td><td>16.4%<\/td><\/tr><\/tbody><\/table><\/figure><p>Track live <strong>Sun Pharma<\/strong> fundamentals and analyst ratings on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sun_Pharma_Share_Price_Targets_%E2%80%94_Short-Term_12-Month_Long-Term\"><\/span><strong>Sun Pharma Share Price Targets \u2014 Short-Term, 12-Month &amp; Long-Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Access premium analyst research on Univest<\/strong><\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Scenario<\/strong><\/td><td><strong>Target<\/strong><\/td><td><strong>Basis<\/strong><\/td><\/tr><tr><td>Short-Term (3-6M)<\/td><td>Rs 1,900<\/td><td>Technical support; near-term catalyst<\/td><\/tr><tr><td>12-Month Consensus<\/td><td>Rs 1,900-2,100<\/td><td>Analyst consensus based on current fundamentals<\/td><\/tr><tr><td>Bull Case (FY28)<\/td><td>Rs 2,500<\/td><td>Full execution of growth catalysts below<\/td><\/tr><tr><td>Bear Case<\/td><td>Rs 1,300<\/td><td>Materialisation of key risks below<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bull_Case_%E2%80%94_What_Has_to_Go_Right_for_Sun_Pharma\"><\/span><strong>Bull Case \u2014 What Has to Go Right for Sun Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_US_specialty_franchise_Ilumya_Cequa_Odomzo_generating_12_billion_and_growing_at_15_CC_annually\"><\/span><strong>1. US specialty franchise (Ilumya, Cequa, Odomzo) generating $1.2+ billion and growing at 15% CC annually<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>US specialty franchise (Ilumya, Cequa, Odomzo) generating $1.2+ billion and growing at 15% CC annually<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_India_branded_generics_market_leadership_10_market_share_in_key_therapy_areas\"><\/span><strong>2. India branded generics market leadership (10%+ market share in key therapy areas)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>India branded generics market leadership (10%+ market share in key therapy areas)<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_GLP-1_Semaglutide-class_obesity_drug_GL0034_in_Phase_2\"><\/span><strong>3. GLP-1 (Semaglutide-class) obesity drug GL0034 in Phase 2<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>potentially transformational if Phase 3 data positive<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Organon_acquisition_optionality\"><\/span><strong>4. Organon acquisition optionality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>if executed successfully, doubles US commercial scale<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Emerging_market_specialty_expansion_in_dermatology_and_ophthalmology_across_45_countries\"><\/span><strong>5. Emerging market specialty expansion in dermatology and ophthalmology across 45+ countries<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Emerging market specialty expansion in dermatology and ophthalmology across 45+ countries<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bear_Case_%E2%80%94_Key_Risks_to_the_Sun_Pharma_Share_Price_Target\"><\/span><strong>Bear Case \u2014 Key Risks to the Sun Pharma Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_1_Ilumya_biosimilar_entry_in_FY27-28_materially_reducing_the_highest-margin_US_product_revenue\"><\/span><strong>Risk 1: Ilumya biosimilar entry in FY27-28 materially reducing the highest-margin US product revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Ilumya biosimilar entry in FY27-28 materially reducing the highest-margin US product revenue<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_2_Organon_acquisition_completing_with_adverse_terms_creating_leveraged_balance_sheet_without_commensurate_earnings_accretion\"><\/span><strong>Risk 2: Organon acquisition completing with adverse terms, creating leveraged balance sheet without commensurate earnings accretion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Organon acquisition completing with adverse terms, creating leveraged balance sheet without commensurate earnings accretion<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Risk_3_US_26_pharma_tariff_expansion_beyond_APIs_to_finished_formulations\"><\/span><strong>Risk 3: US 26% pharma tariff expansion beyond APIs to finished formulations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>US 26% pharma tariff expansion beyond APIs to finished formulations<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Institutional_Sentiment_and_Technical_Analysis\"><\/span><strong>Institutional Sentiment and Technical Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Sun Pharma has 21.8% FII holding and 16.4% DII holding. High FII ownership of 21.8% means the stock is sensitive to global risk-off events \u2014 FII selling can be disproportionate to any specific negative news.<\/p><p>Technically, Sun Pharma is trading at Rs 1,580 against a 52-week range of Rs 1,480 to Rs 2,000. The -20% 1-year return positions the stock in negative territory \u2014 creating both risk of further downside and opportunity for mean reversion. The 12-month analyst target of Rs 1,900-2,100 implies the stock is expected to recover meaningfully from current depressed levels.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for real-time research and analyst updates.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion_%E2%80%94_Our_View_on_name_Share_Price_Target\"><\/span><strong>Conclusion \u2014 Our View on ${name} Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Sun Pharma at Rs 1,580 is at its most attractive entry point in 18 months. The specialty US business ($1.2 billion and growing), India market leadership, and emerging market expansion provide a diversified growth platform. The Organon deal uncertainty is a risk, not a certainty. At 38x P\/E on FY26 earnings, the stock offers value if US specialty continues growing at 15%. 12-month target of Rs 1,900-2,100 implies 20-33% upside.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for SEBI-registered analyst recommendations \u2014 entry, target, stop-loss.<\/strong><\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q1_What_is_Sun_Pharma_share_price_target_2026\"><\/span><strong>Q1. What is Sun Pharma share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma share price target for 2026 is Rs 1,900-2,100 based on analyst consensus. The bull case target is Rs 2,500 and the bear case is Rs 1,300. These are analyst estimates, not guaranteed returns.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q2_Is_Sun_Pharma_a_good_buy_now\"><\/span><strong>Q2. Is Sun Pharma a good buy now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma is trading at Rs 1,580 against a 52-week range of Rs 1,480 to Rs 2,000. Analyst consensus target of Rs 1,900-2,100 implies upside from current levels. Consult a SEBI-registered financial advisor before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q3_What_is_Sun_Pharmas_current_valuation\"><\/span><strong>Q3. What is Sun Pharma&#8217;s current valuation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Sun Pharma trades at a trailing P\/E of 38x and price-to-book of 6.8x with a market capitalisation of Rs 3.8L Cr. The stock&#8217;s valuation relative to earnings growth determines the appropriate entry point.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q4_What_are_the_key_risks_for_Sun_Pharma\"><\/span><strong>Q4. What are the key risks for Sun Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Key risks for Sun Pharma include the factors outlined in the Bear Case section of this article. Ilumya biosimilar entry in FY27-28 materially reducing the highest-margin US product revenue is the primary near-term risk to watch.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q5_Where_can_I_track_Sun_Pharma_share_price_live\"><\/span><strong>Q5. Where can I track Sun Pharma share price live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Track Sun Pharma share price live, quarterly results, FII\/DII activity, and analyst ratings on the Univest Screener at univest.in\/screeners. Download the Univest iOS or Android App for daily research.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates and may change. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.For more stock research, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Articles\"><\/span>Recent Articles<span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/why-is-krbl-share-price-falling\"><strong>Why is KRBL Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-reliance-infrastructures-share-price-falling\"><strong>Why is Reliance Infrastructures Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-mahanagar-gas-share-price-falling\"><strong>Why is Mahanagar Gas Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/why-is-happiest-minds-share-price-falling\"><strong>Why is Happiest Minds Share Price Falling? Check Next Share Price Target&nbsp;<\/strong><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sun Pharma (Pharmaceuticals \/ Specialty) is trading at Rs 1,580 as of April 2026, with a 52-week range from Rs 1,480 to Rs 2,000 and a 1-year return of -20%. The analyst consensus 12-month Sun Pharma share price target stands at Rs 1,900-2,100 \u2014 implying meaningful potential movement from current levels. Whether you are a<\/p>\n","protected":false},"author":26,"featured_media":70224,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-70219","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1776074541:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_focus_keyword":["Sun Pharma"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":["Sun Pharma Share Price Target 2026: Analyst Estimates, Bull &amp; Bear Case"],"rank_math_description":["Sun Pharma share price target 2026 \u2014 analyst consensus Rs 1,900-2,100. CMP Rs 1,580, 12M target, bull case Rs 2,500, bear case Rs 1,300. Full analysis.\n"],"_thumbnail_id":["70224"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7920"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/13152948\/sun-pharma-target_.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=70219"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70219\/revisions"}],"predecessor-version":[{"id":70225,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/70219\/revisions\/70225"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/70224"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=70219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=70219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=70219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}